![]() |
Name |
Hypocrellin b
|
Molecular Formula | C30H24O9 | |
IUPAC Name* |
12-acetyl-9,17-dihydroxy-5,10,16,21-tetramethoxy-13-methylhexacyclo[13.8.0.02,11.03,8.04,22.018,23]tricosa-1(15),2(11),3(8),4(22),5,9,12,16,18(23),20-decaene-7,19-dione
|
|
SMILES |
CC1=C(C2=C3C4=C(C1)C(=C(C5=C4C(=C6C3=C(C(=O)C=C6OC)C(=C2OC)O)C(=CC5=O)OC)O)OC)C(=O)C
|
|
InChI |
InChI=1S/C30H24O9/c1-10-7-12-18-23-19(27(34)29(12)38-5)13(32)8-15(36-3)21(23)22-16(37-4)9-14(33)20-25(22)24(18)26(17(10)11(2)31)30(39-6)28(20)35/h8-9,34-35H,7H2,1-6H3
|
|
InChIKey |
SBMXTMAIKRQSQE-UHFFFAOYSA-N
|
|
Synonyms |
hypocrellin b; Hypocrellin C; 123940-54-5; 149457-83-0; 12-acetyl-9,17-dihydroxy-5,10,16,21-tetramethoxy-13-methylhexacyclo[13.8.0.02,11.03,8.04,22.018,23]tricosa-1(15),2(11),3(8),4(22),5,9,12,16,18(23),20-decaene-7,19-dione; 1H-Cyclohepta[ghi]perylene-6,11-dione,3-acetyl-5,12-dihydroxy-4,8,9,13-tetramethoxy-2-methyl-; Shiraiachrome C; CHEMBL2029624; CHEMBL4793204; SCHEMBL13121633; SCHEMBL14302232; ZINC689953; HY-N1453; HY-N6081; YEA94054; MFCD00467741; AKOS037514883; CS-0016899; CS-0032509; (E)-13-acetyl-3,8-dihydroxy-1,5,6,10-tetramethoxy-12-methyl-2H-cyclohepta[ghi]perylene-2,9(11H)-dione
|
|
CAS | 123940-54-5 | |
PubChem CID | 1023768 | |
ChEMBL ID | CHEMBL2029624 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 528.5 | ALogp: | 4.3 |
HBD: | 2 | HBA: | 9 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 129.0 | Aromatic Rings: | 6 |
Heavy Atoms: | 39 | QED Weighted: | 0.244 |
Caco-2 Permeability: | -5.1 | MDCK Permeability: | 0.00000940 |
Pgp-inhibitor: | 0.223 | Pgp-substrate: | 0.183 |
Human Intestinal Absorption (HIA): | 0.898 | 20% Bioavailability (F20%): | 0 |
30% Bioavailability (F30%): | 0.007 |
Blood-Brain-Barrier Penetration (BBB): | 0.002 | Plasma Protein Binding (PPB): | 66.03% |
Volume Distribution (VD): | 0.64 | Fu: | 45.57% |
CYP1A2-inhibitor: | 0.276 | CYP1A2-substrate: | 0.981 |
CYP2C19-inhibitor: | 0.03 | CYP2C19-substrate: | 0.389 |
CYP2C9-inhibitor: | 0.361 | CYP2C9-substrate: | 0.835 |
CYP2D6-inhibitor: | 0.007 | CYP2D6-substrate: | 0.162 |
CYP3A4-inhibitor: | 0.021 | CYP3A4-substrate: | 0.061 |
Clearance (CL): | 1.126 | Half-life (T1/2): | 0.417 |
hERG Blockers: | 0.002 | Human Hepatotoxicity (H-HT): | 0.054 |
Drug-inuced Liver Injury (DILI): | 0.972 | AMES Toxicity: | 0.135 |
Rat Oral Acute Toxicity: | 0.112 | Maximum Recommended Daily Dose: | 0.237 |
Skin Sensitization: | 0.471 | Carcinogencity: | 0.015 |
Eye Corrosion: | 0.012 | Eye Irritation: | 0.867 |
Respiratory Toxicity: | 0.185 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004029 | ![]() |
0.726 | D09DHY | ![]() |
0.338 | ||
ENC003190 | ![]() |
0.672 | D06GCK | ![]() |
0.326 | ||
ENC001117 | ![]() |
0.672 | D02LZB | ![]() |
0.312 | ||
ENC001118 | ![]() |
0.621 | D01FFA | ![]() |
0.250 | ||
ENC001491 | ![]() |
0.456 | D0C1SF | ![]() |
0.248 | ||
ENC001501 | ![]() |
0.451 | D03RTK | ![]() |
0.248 | ||
ENC002093 | ![]() |
0.451 | D0Y7TS | ![]() |
0.240 | ||
ENC002002 | ![]() |
0.442 | D0V8HJ | ![]() |
0.234 | ||
ENC003042 | ![]() |
0.439 | D0V6OA | ![]() |
0.234 | ||
ENC003154 | ![]() |
0.432 | D0G4KG | ![]() |
0.233 |